Compare Eli Lilly And Co (LLY) vs S&P500 ETF (SPY) Price & Performance

Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.

LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.

SPY, the SPDR S&P 500 ETF Trust, trades at $772.90 with minimal daily movement (-0.02%). Technical indicators show a bullish trend with moving averages supporting upside momentum, though oscillators signal potential overbought conditions. The ETF maintains its position as the world's largest fund with approximately $676 billion in assets. Recent news highlights the S&P 500 reaching record highs while facing valuation concerns with the Shiller P/E ratio at 42, the highest since the dot-com era.

The ETF's outlook remains positive with institutional targets pointing toward 8,000 levels, though elevated valuations and weak market breadth present near-term risks. Dividend income continues to attract investors with reliable distributions, but fee comparisons with competing funds highlight cost considerations for long-term holders.